Get access

Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients

Authors

  • Y. Nozawa,

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author
  • T. Umemura,

    Corresponding author
    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    • Correspondence

      Takeji Umemura, MD, PhD

      Department of Medicine

      Shinshu University School of Medicine

      3-1-1 Asahi

      Matsumoto 390-8621

      Japan

      Tel: +81 263 37 2634

      Fax: +81 263 32 9412

      e-mail: tumemura@shinshu-u.ac.jp

      and

      Masao Ota, PhD

      Department of Legal Medicine

      Shinshu University School of Medicine

      3-1-1 Asahi

      Matsumoto 390-8621

      Japan

      Tel: +81 263 37 3217

      Fax: +81 263 37 3084

      e-mail: otamasao@shinshu-u.ac.jp

    Search for more papers by this author
  • Y. Katsuyama,

    1. Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan
    Search for more papers by this author
  • S. Shibata,

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author
  • T. Kimura,

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author
  • S. Morita,

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author
  • S. Joshita,

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author
  • M. Komatsu,

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author
  • A. Matsumoto,

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author
  • K. Yoshizawa,

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author
  • M. Ota,

    Corresponding author
    1. Department of Legal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
    • Correspondence

      Takeji Umemura, MD, PhD

      Department of Medicine

      Shinshu University School of Medicine

      3-1-1 Asahi

      Matsumoto 390-8621

      Japan

      Tel: +81 263 37 2634

      Fax: +81 263 32 9412

      e-mail: tumemura@shinshu-u.ac.jp

      and

      Masao Ota, PhD

      Department of Legal Medicine

      Shinshu University School of Medicine

      3-1-1 Asahi

      Matsumoto 390-8621

      Japan

      Tel: +81 263 37 3217

      Fax: +81 263 37 3084

      e-mail: otamasao@shinshu-u.ac.jp

    Search for more papers by this author
  • E. Tanaka

    1. Department of Medicine, Division of Hepatology and Gastroenterology, Shinshu University School of Medicine, Matsumoto, Japan
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Erratum Volume 83, Issue 3, 236, Article first published online: 20 February 2014

Abstract

A genetic polymorphism of the newly discovered interferon-λ 4 (IFNL4) gene was associated with hepatitis C virus (HCV) clearance in individuals of African ancestry. To assess whether a dinucleotide variant of IFNL4 (ss469415590) also affected treatment outcome of antiviral therapy in Japan, we genotyped 213 patients with chronic genotype 1 HCV infection and 176 healthy subjects. The ΔG allele was associated with treatment failure [odds ratio (OR) 4.73, P = 0.019], as was the IFL3 rs8099917 single nucleotide polymorphism (SNP) (OR 5.06, P = 0.068). The correlation between ss469415590 and rs8099917 was high (r2 = 0.92, D′ = 0.98). Multivariate analysis revealed that the rs8099917 SNP was independently associated with treatment failure (OR 5.28, P = 0.009). Therefore, ss469415590 may be another predictive marker of antiviral therapy outcome in the Japanese population.

Ancillary